JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2014, 63(4):152-159 | DOI: 10.36290/csf.2014.031

Metabolic syndrome - dysregulation of adipose tissue endocrine function

Kateřina Horská1, Jana Kučerová2,3, Pavel Suchý1, Hana Kotolová1,*
1 Ústav humánní farmakologie a toxikologie FaF, Veterinární a Farmaceutická Univerzita, Brno, ČR
2 Lékařská fakulta MU, Farmakologický ústav, Brno
3 Masarykova Univerzita, CEITEC - Středoevropský technologický institut, Brno, ČR

Metabolic syndrome, acondition increasing cardiovascular morbidity, mortality and risk for diabetes mellitus type 2, is currently worldwide reaching epidemic proportions. This complex disorder represents an urgent challenge for new pharmacotherapeutic strategies formulation. Pathophysiological mechanisms underlying metabolic syndrome are not completely understood, nevertheless growing evidence is supporting the hypothesis that multiple metabolic dysregulations do contribute to its development. Apotential target for pharmacological intervention is considered to be dysregulation of adipose tissue endocrine/paracrine function. Specific adipokines, proteins secreted by the adipose tissue, with some pleiotropic effects, have been identified with strong association to regulation of energy metabolism, appetite, insulin signaling, tissue insulin sensitivity and the proinflammatory state related to metabolic syndrome. The aim of this paper is to provide abrief overview of endocrine/paracrine functions of the adipose tissue with regard to metabolic syndrome development and pathophysiology and particular adipokines as potential targets for innovative pharmacotherapeutic approaches.

Keywords: metabolic syndrome; insulin resistance; adipose tissue; adipokines
Grants and funding:

This work was supported by: Project Internal Grant Agency (IGA) VFU Brno (48/2014/FaF), Project Internal Agency for Education (IVA) VFU Brno (2014FaF/3140/071), Project of specific research at the Masaryk University (MUNI/A/0886/2013) and Project "CEITEC - Central European Institute of Technology" (CZ.1.05/1.1.00/02.0068) from European Regional Development Fund.

Received: June 4, 2014; Accepted: July 4, 2014; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horská K, Kučerová J, Suchý P, Kotolová H. Metabolic syndrome - dysregulation of adipose tissue endocrine function. Čes. slov. farm. 2014;63(4):152-159. doi: 10.36290/csf.2014.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reaven G. M. Syndrome X. Blood Press Suppl. 1992; 4, 13-16. Go to original source... Go to PubMed...
    2. Kaplan N. M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 1989; 149, 1514-1520. Go to original source... Go to PubMed...
    3. Mani A., Radhakrishnan J., Wang H., Mani A., Mani M. A., Nelson-Williams C., Carew K. S., Mane S., Najmabadi H., Wu D., Lifton R. P. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315, 1278-1282. Go to original source... Go to PubMed...
    4. Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 1996; 334, 374-381. Go to original source... Go to PubMed...
    5. Aykan A. C., Gul I., Kalaycioglu E., Gokdeniz T., Hatem E., Mentese U., Sahin Yildiz B., Yildiz M. Is metabolic syndrome related with coronary artery disease severity and complexity: An observational study about IDF and AHA/NHLBI metabolic syndrome definitions? Cardiol. J. 2013; 62.18_S2: C196-C197. Go to original source...
    6. Alberti K. G., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J. C., James W. P., Loria C. M., Smith S. C., Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120, 1640-1645. Go to original source... Go to PubMed...
    7. Chen S., Chen Y., Liu X., Li M., Wu B., Li Y., Liang Y., Shao X., Holthofer H., Zou H. Insulin resistance and metabolic syndrome in normal-weight individuals. Endocrine 2013; 1-9. Go to original source... Go to PubMed...
    8. Ruderman N. B., Carling D., Prentki M., Cacicedo J. M. AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 2013; 123, 2764-2772. Go to original source... Go to PubMed...
    9. Stettler N., Murphy M. M., Barraj L. M., Smith K. M., Ahima R. S. Systematic review of clinical studies related to pork intake and metabolic syndrome or its components. Diabetes Metab. Syndr. Obes. 2013; 6, 347-357. Go to original source... Go to PubMed...
    10. Eckel R. H. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc. Nutr. Soc. 2007; 66, 82-95. Go to original source... Go to PubMed...
    11. Alemany M. Relationship between energy dense diets and white adipose tissue inflammation in metabolic syndrome. Nutr. Res. 2013; 33, 1-11. Go to original source... Go to PubMed...
    12. Tracy R. P. Inflammation, the metabolic syndrome and cardiovascular risk. Int. J. Clin. Pract. Suppl. 2003; 10-17.
    13. Xu H., Barnes G. T., Yang Q., Tan G., Yang D., Chou C. J., Sole J., Nichols A., Ross J. S., Tartaglia L. A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003; 112, 1821-1830. Go to original source... Go to PubMed...
    14. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259, 87-91. Go to original source... Go to PubMed...
    15. Athyros V. G., Tziomalos K., Karagiannis A., Anagnostis P., Mikhailidis D. P. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr. Drug Targets 2010; 11, 122-135. Go to original source... Go to PubMed...
    16. Haas B., Schlinkert P., Mayer P., Eckstein N. Targeting adipose tissue. Diabetol. Metab. Syndr. 2012; 4, 43. Go to original source... Go to PubMed...
    17. Galic S., Oakhil, J. S., Steinberg G. R. Adipose tissue as an endocrine organ. Mol. Cell Endocrinol. 2010; 316, 129-139. Go to original source... Go to PubMed...
    18. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J. M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372, 425-432. Go to original source... Go to PubMed...
    19. Houseknecht K. L., Portocarrero C. P. Leptin and its receptors: regulators of whole-body energy homeostasis. Domest. Anim. Endocrinol. 1998; 15, 457-475. Go to original source... Go to PubMed...
    20. Chen H., Charlat O., Tartaglia L. A., Woolf E. A., Weng X., Ellis S. J., Lakey N. D., Culpepper J., Moore K. J., Breitbart R. E., Duyk G. M., Tepper R. I., Morgenstern J. P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84, 491-495. Go to original source... Go to PubMed...
    21. Margetic S., Gazzola C., Pegg G. G., Hill R. A. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 2002; 26, 1407-1433. Go to original source... Go to PubMed...
    22. Ahima R. S. Revisiting leptin's role in obesity and weight loss. J. Clin. Invest. 2008; 118, 2380-2383. Go to original source... Go to PubMed...
    23. Tartaglia L. A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G. J., Campfield L. A., Clark F. T., Deeds J., Muir C., Sanker S., Moriarty A., Moore K. J., Smutko J. S., Mays G. G., Wool E. A., Monroe C. A., Tepper R. I. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83, 1263-1271. Go to original source... Go to PubMed...
    24. Baskin D. G., Figlewicz Lattemann D., Seeley R. J., Woods S. C., Porte D., Jr., Schwartz M. W. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res. 1999; 848, 114-123. Go to original source... Go to PubMed...
    25. Rabe K., Lehrke M., Parhofer K. G., Broedl U. C. Adipokines and insulin resistance. Mol. Med. 2008; 14, 741-751. Go to original source... Go to PubMed...
    26. Bjorbaek C. Central leptin receptor action and resistance in obesity. J. Investig. Med. 2009; 57, 789-794. Go to original source... Go to PubMed...
    27. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 1996; 221, 286-289. Go to original source... Go to PubMed...
    28. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005; 26, 439-451. Go to original source... Go to PubMed...
    29. Bjursell M., Ahnmark A., Bohlooly Y. M., William-Olsson L., Rhedin M., Peng X. R., Ploj K., Gerdin A. K., Arnerup G., Elmgren A., Berg A. L., Oscarsson J., Linden D. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007; 56, 583-593. Go to original source... Go to PubMed...
    30. Kershaw E. E., Flier J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004; 89, 2548-2456. Go to original source... Go to PubMed...
    31. Hara K., Boutin P., Mori Y., Tobe K., Dina C., Yasuda K., Yamauchi T., Otabe S., Okada T., Eto K., Kadowaki H., Hagura R., Akanuma Y., Yazaki Y., Nagai R., Taniyama M., Matsubara K., Yoda M., Nakano Y., Tomita M., Kimura S., Ito C., Froguel P., Kadowaki T. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002; 51, 536-540. Go to original source... Go to PubMed...
    32. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., Nagai M., Matsuzawa Y., Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004; 68, 975-981. Go to original source... Go to PubMed...
    33. Kizer J. R. A tangled threesome: adiponectin, insulin sensitivity, and adiposity: can Mendelian randomization sort out causality? Diabetes 2013; 62, 1007-1009. Go to original source... Go to PubMed...
    34. Kubota N., Yano W., Kubota T., Yamauchi T., Itoh S., Kumagai H., Kozono H., Takamoto I., Okamoto S., Shiuchi T., Suzuki R., Satoh H., Tsuchida A., Moroi M., Sugi K., Noda T., Ebinuma H., Ueta Y., Kondo T., Araki E., Ezaki O., Nagai R., Tobe K., Terauchi Y., Uek K., Minokoshi Y., Kadowaki T. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007; 6, 55-68. Go to original source... Go to PubMed...
    35. Tsao T. S., Lodish H. F., Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur. J. Pharmacol. 2002; 440, 213-221. Go to original source... Go to PubMed...
    36. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M. R., Stumvoll M., Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54, 2911-2916. Go to original source... Go to PubMed...
    37. Samal B., Sun Y., Stearns G., Xie C., Suggs S., Mcniece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol. 1994; 14, 1431-1437. Go to original source...
    38. Chen M. P., Chung F. M., Chang D. M., Tsai J. C., Huang H. F., Shin S. J., Lee Y. J. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006; 91, 295-299. Go to original source... Go to PubMed...
    39. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem. 2008; 15, 1851-1862. Go to original source... Go to PubMed...
    40. Yang R. Z., Lee M. J., Hu H., Pray J., Wu H. B., Hansen B. C., Shuldiner A. R., Fried S. K., Mclenithan J. C., Gong D. W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006; 290, E1253-1261. Go to original source... Go to PubMed...
    41. Brunetti L., Di Nisio C., Recinella L., Chiavaroli A., Leone S., Ferrante C., Orlando G., Vacca M. Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 2011; 32, 1866-1871. Go to original source... Go to PubMed...
    42. Tan B. K., Adya R., Farhatullah S., Lewandowski K. C., O'Hare P., Lehnert H., Randeva H. S. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57, 801-808. Go to original source... Go to PubMed...
    43. Brunetti L., Orlando G., Ferrante C., Recinella L., Leone S., Chiavaroli A., Di Nisio C., Shohreh R., Manippa F., Ricciuti A., Vacca M. Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides 2013; 44, 66-74. Go to original source... Go to PubMed...
    44. Kloting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schon M. R., Stumvoll M., Bluher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 2006; 339, 430-436. Go to original source... Go to PubMed...
    45. Ye Y., Hou X. H., Pan X. P., Lu J. X., Jia W. P. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin. Med. J. (Engl). 2009; 122, 2530-2533.
    46. Bluher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012; 41, 176-182. Go to original source... Go to PubMed...
    47. Jeong E., Youn B. S., Kim D. W., Kim E. H., Park J. W., Namkoong C., Jeong J. Y., Yoon S. Y., Park J. Y., Lee K. U., Kim M. S. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J. Clin. Endocrinol. Metab. 2010; 95, 1869-1875. Go to original source... Go to PubMed...
    48. Handisurya A., Riedl M., Vila G., Maier C., Clodi M., Prikoszovich T., Ludvik B., Prager G., Luger A., Kautzky- -Willer A. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes. Surg. 2010; 20, 198-203. Go to original source... Go to PubMed...
    49. Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., Patel H. R., Ahima R. S., Lazar M. A. The hormone resistin links obesity to diabetes. Nature 2001; 409, 307-312. Go to original source... Go to PubMed...
    50. Wang H., Chu W. S., Hemphill C., Elbein S. C. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J. Clin. Endocrinol. Metab. 2002; 87, 2520-2524. Go to original source... Go to PubMed...
    51. Barnes K. M., Miner J. L. Role of resistin in insulin sensitivity in rodents and humans. Curr. Protein. Pept. Sci. 2009; 10, 96-107. Go to original source... Go to PubMed...
    52. Steppan C. M., Lazar M. A. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 2002; 13, 18-23. Go to original source... Go to PubMed...
    53. Kosari S., Rathner J. A., Badoer E. Central resistin enhances renal sympathetic nerve activity via phosphatidylinositol 3-kinase but reduces the activity to brown adipose tissue via extracellular signal-regulated kinase 1/2. J. Neuroendocrinol. 2012; 24, 1432-1439. Go to original source... Go to PubMed...
    54. Rodriguez-Pacheco F., Novelle M. G., Vazquez M. J., Garcia-Escobar E., Soriguer F., Rojo-Martinez G., Garcia-Fuentes E., Malagon M. M., Dieguez, C. Resistin regulates pituitary lipid metabolism and inflammation in vivo and in vitro. Mediators Inflamm. 2013; Article 479739. http://www.hindawi.com/journals/mi/2013/479739/abs/. Go to original source...
    55. Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006; 1, e31. http://www.plosone.org. Go to original source... Go to PubMed...
    56. Kaser S., Kaser A., Sandhofer A., Ebenbichler C. F., Tilg H., Patsch J. R. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem. Biophys. Res. Commun. 2003; 309, 286-290. Go to original source... Go to PubMed...
    57. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 2005; 174, 5789-5795. Go to original source... Go to PubMed...
    58. Savage D. B., Sewter C. P., Klenk E. S., Segal D. G., Vidal-Puig A., Considine R. V.,, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50, 2199-2202. Go to original source... Go to PubMed...
    59. Patel L., Buckels A. C., Kinghorn I. J., Murdock P. R., Holbrook J. D., Plumpton C., Macphee C. H., Smith S. A. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem. Biophys. Res. Commun. 2003; 300, 472-476. Go to original source... Go to PubMed...
    60. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H., Kawahara Y., Yamazaki Y., Ogata M., Hasegawa G., Nakamura N., Yoshikawa T., Nakano K., Ohta M. Enzyme-linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes. Clin. Chim. Acta. 2004; 339, 57-63. Go to original source... Go to PubMed...
    61. Lee J. H., Chan J. L, Yiannakouris N, Kontogianni M, Estrada E, Seip R., Orlova C., Mantzoros C. S. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 2003; 88, 4848-4856. Go to original source... Go to PubMed...
    62. Azuma K., Katsukawa F., Oguchi S., Murata M., Yamazaki H., Shimada, A., Saruta, T. Correlation between serum resistin level and adiposity in obese individuals. Obes. Res. 2003; 11, 997-1001. Go to original source... Go to PubMed...
    63. Silha J. V., Krsek M, Skrha J. V., Sucharda P, Nyomba B. L., Murphy, L. J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur. J. Endocrinol. 2003; 149, 331-335. Go to original source... Go to PubMed...
    64. Baar R. A., Dingfelder C. S., Smith L. A., Bernlohr D. A., Wu C., Lange A. J., Parks E. J. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice. Am. J. Physiol. Endocrinol. Metab. 2005; 288, E187-193. Go to original source... Go to PubMed...
    65. Xu A., Tso A. W., Cheung B. M., Wang Y., Wat N. M., Fong C. H., Yeung D. C., Janus E. D., Sham P. C., Lam K. S. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115, 1537-1543. Go to original source... Go to PubMed...
    66. Haider D. G., Schindler K., Bohdjalian A., Prager G., Luger A., Wolzt M., Ludvik B. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes. Metab. 2007; 9, 761-763. Go to original source... Go to PubMed...
    67. Simon I., Escote X., Vilarrasa N., Gomez J., Fernandez-Real J. M., Megia A., Gutierrez C., Gallart L., Masdevall C., Vendrell J. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity 2009; 17, 1124-1128. Go to original source... Go to PubMed...
    68. Stejskal D., Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur. J. Clin. Invest. 2006; 36, 621-625. Go to original source... Go to PubMed...
    69. Bronsky J., Karpisek M., Bronska E., Pechova M., Jancikova B., Kotolova H., Stejskal D., Prusa R., Nevoral J. Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk. Clin. Chem. 2006; 52, 1763-1770. Go to original source... Go to PubMed...
    70. Karpisek M., Stejskal D., Kotolova H., Kollar P., Janoutova G., Ochmanova R., Cizek L., Horakova, D., Yahia R. B., Lichnovska R., Janout V. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur. J. Clin. Invest. 2007; 37, 637-642. Go to original source... Go to PubMed...
    71. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002; 8, 731-737. Go to original source... Go to PubMed...
    72. Mooney R. A. Counterpoint: Interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007; 102, 816-868. Go to original source... Go to PubMed...
    73. Sparks J. D., Cianci J., Jokinen J., Chen L. S., Sparks C. E. Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B. Am. J. Physiol. Gastrointest Liver. Physiol. 2010; 299, G980-989. Go to original source... Go to PubMed...
    74. Bruun J. M., Lihn A. S., Verdich C., Pedersen S. B., Toubro S., Astrup A., Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 2003; 285, E527-533. Go to original source... Go to PubMed...
    75. Trujillo M. E., Sullivan S., Harten I., Schneider S. H., Greenberg A. S., Fried S. K. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab. 2004; 89, 5577-5582. Go to original source... Go to PubMed...
    76. Richter E. A., Garetto L. P., Goodman M. N., Ruderman N. B. Muscle glucose metabolism following exercise in the rat: increased sensitivity to insulin. J. Clin. Invest. 1982; 69, 785-793. Go to original source... Go to PubMed...
    77. Al-Khalili L., Bouzakri K., Glund S., Lonnqvist F., Koistinen H. A., Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 2006; 20, 3364-3375. Go to original source... Go to PubMed...
    78. Glund S., Deshmukh A., Long Y. C., Moller T., Koistinen H. A., Caidahl K., Zierath J. R., Krook A. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 2007; 56, 1630-1637. Go to original source... Go to PubMed...
    79. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J. F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148, 241-251. Go to original source... Go to PubMed...
    80. Lagathu C., Yvan-Charvet L., Bastard J. P., Maachi M., Quignard-Boulange A., Capeau J., Caron M. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49, 2162-2173. Go to original source... Go to PubMed...
    81. Tchernof A., Després J. Pathophysiology of human visceral obesity: an update. Physiological reviews 2013; 93.1, 359-404. Go to original source... Go to PubMed...
    82. Ibrahim M. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity reviews 2010; 11, 11-18. Go to original source... Go to PubMed...
    83. Chou K., Perry, C. M. Metreleptin: first global approval. Drugs 2013; 73/9, 989-997. Go to original source... Go to PubMed...
    84. FDA. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm387060.htm.
    85. Fiaschi T., Magherini F., Gamberi T., Modesti P. A., Modesti, A. Adiponectin as a tissue regenerating hormone: more than a metabolic function. Cellular and Molecular Life Sciences 2014; 71.10, 1917-1925. Go to original source... Go to PubMed...
    86. Kakafika A. I., Mikhailidis D. P., Karagiannis A., Athyros V. G. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J. Clin. Pharmacol. 2007; 47, 642-652. Go to original source... Go to PubMed...
    87. Perkins J. M., Davis S. N. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr. Diab. Rep. 2008; 8, 12-19. Go to original source... Go to PubMed...
    88. Vemuri V. K., Janero D. R., Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav. 2008; 93, 671-686. Go to original source... Go to PubMed...
    89. De Luis D. A., Gonzalez Sagrado M., Aller R., Izaola O., Conde R. Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification. Diabetes Metab. Res. Rev. 2011; 27, 506-511. Go to original source... Go to PubMed...
    90. Merroun I., Sanchez-Gonzalez C., Martinez R., Lopez-Chaves C., Porres J. M., Aranda P., Llopis J., Galisteo M., Zarzuelo A., Errami M., Lopez-Jurado M. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats. Metabolism 2013; 62, 1641-1650. Go to original source... Go to PubMed...
    91. Slavic S., Lauer D., Sommerfeld M., Kemnitz U. R., Grzesiak A., Trappiel M., Thone-Reineke C., Baulmann J., Paulis L., Kappert K., Kintscher U., Unger T., Kaschina E. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J. Mol. Med. (Berl.). 2013; 91, 811-823. Go to original source... Go to PubMed...
    92. Chartoumpekis D. V., Kensler T. W. New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr. Diabetes Rev. 2013; 9, 137-145. Go to original source... Go to PubMed...
    93. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013; 39, 197-208. Go to original source... Go to PubMed...
    94. Anagnostis P., Katsiki N., Adamidou F., Athyros V. G., Karagiannis A., Kita M., Mikhailidis D. P. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 2013; 62, 21-33. Go to original source... Go to PubMed...
    95. Ricci-Cabello I., Herrera M. O., Artacho R. Possible role of milk-derived bioactive peptides in the treatment and prevention of metabolic syndrome. Nutr. Rev. 2012; 70, 241-155. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.